Atreon Orthopedics

What Atreon Orthopedics does

Atreon Orthopedics is a privately held medical device company headquartered in Dublin (Columbus metro), Ohio, that develops and commercializes fully synthetic, bioresorbable electrospun nanofiber scaffolds for tendon-to-bone and soft tissue repair. Founded in 2016 in partnership with Nanofiber Solutions (which provides manufacturing and electrospinning expertise), the company's Autobiologic platform uses Poly Glycolic Acid (PGA) and Poly Lactide co-Caprolactone (PLCL) polymers engineered to mimic extracellular matrix, wick and retain autologous biologics at the repair site, and support native tissue remodeling rather than scar formation. Its commercial product portfolio includes the FDA 510(k)-cleared ROTIUM Bioresorbable Wick for the tendon-bone interface (K183236), BioCharge Autobiologic Matrix for bursal-side reinforcement of rotator cuff repairs (K241912), Phoenix Wound Matrix for non-healing wound reconstruction, and ROTIUM LoPro for tendon wrapping applications, along with the BioStack combination kit. The lead indication is rotator cuff repair, supported by peer-reviewed clinical evidence showing a 7.1% failure rate with ROTIUM versus 50% in unaugmented controls over 17-month follow-up and cumulative use in 12,000+ procedures as of late 2024/early 2025.

Atreon generates revenue through hardware sales of its FDA-cleared Class II devices to orthopedic surgeons and healthcare facilities, distributed via a US distributor partner network and direct field sales, with initial international reach into Taiwan and select other countries. Its target customer segments include orthopedic surgeons specializing in sports medicine and shoulder surgery (primary), foot & ankle, hip, and knee tendon repair surgeons (expanded via 2025 label expansion), and wound care specialists. The company employs a field-sales-led GTM motion anchored on major orthopedic conferences (AAOS, AOSSM, ASES, AOFAS, ACFAS, Shoulder360), clinical-evidence-driven surgeon education, and a co-founding role in the Orthopedic Innovation Consortium.

In May 2025 Atreon announced a merger with RenovoDerm, combining two synthetic biomaterials platforms to expand applications and clinical evidence across additional surgical specialties. The company has raised approximately $10.6M cumulatively across two SEC Form D exempt offerings (2017 and 2025), operates with 1-10 employees, and is led by CEO Ronald Bracken. Strategic priorities reflected in 2025 activity - indication expansion, two new product launches, the RenovoDerm merger, and a $5.18M capital raise from 53 investors - point to active scaling of the commercial organization and product portfolio.

Name

Atreon Orthopedics

Legal name

Atreon Orthopedics LLC

Website

https://atreonortho.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Atreon Orthopedics is a privately held medical device company that develops FDA-cleared, fully synthetic bioresorbable electrospun nanofiber scaffolds (ROTIUM, BioCharge, Phoenix Wound Matrix) for tendon-bone healing, rotator cuff repair, and wound reconstruction, sold to orthopedic surgeons and wound care specialists via US distributor partners and direct field sales.

Ownership category

akta.pro rank

Product category

Orthopedic Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair) (HLAHAEAF)

akta.pro secondary industries

Orthopedic Surgery (Operative Orthopedics) (HLAKALAC), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Bioresorbable scaffolds
• Orthopedic medical devices
• Tendon repair implants
• Rotator cuff augmentation
• Electrospun nanofiber scaffolds

Headquarters

HQ city

Columbus

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations, Infrastructure

Revenue model

1. Medical Device Product Sales: Revenue generated from the sale of FDA-cleared bioresorbable scaffold products including ROTIUM, BioCharge, and Phoenix Wound Matrix to healthcare providers and distributors.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Atreon Orthopedics develops and sells FDA-cleared bioresorbable synthetic electrospun nanofiber scaffolds used as implants during orthopedic tendon repair surgeries. Its products (ROTIUM, BioCharge, ROTIUM LoPro, Phoenix Wound Matrix, and the BioStack combination) are placed at the tendon-bone interface, bursal side, or wound bed to retain the patient's autologous biologic factors and support native tissue remodeling. The company sells these Class II medical devices to orthopedic surgeons, hospitals, and ambulatory surgery centers through distributor partners and direct field sales.

Product overview

Atreon Orthopedics offers a portfolio of synthetic bioresorbable scaffolds based on their Autobiologic™ platform technology. The core products include ROTIUM Bioresorbable Wick (an interpositional scaffold for tendon-bone interface repair), BioCharge Autobiologic Matrix (an onlay scaffold for bursal-side reinforcement), Phoenix Wound Matrix (for wound reconstruction), and Rotium LoPro (for tendon wrapping applications). The company also provides the BioStack Kit, which combines ROTIUM and BioCharge for a dual-sided biologic repair strategy. All products utilize electrospun nanofiber technology made from synthetic polymers (PGA and PLCL) that mimic the extracellular matrix and support native tissue remodeling.

Differentiator

Problem solved

Functional benefit

Brands

• ROTIUM: Bioresorbable wick scaffold for tendon-bone interface repair, used in rotator cuff and other tendon repairs
• BioCharge
• ROTIUM LoPro
• Phoenix Wound Matrix
• BioStack

Products and services

• ROTIUM Bioresorbable Wick Interpositional synthetic bioresorbable scaffold placed at the tendon-bone interface during tendon repair surgery, designed to retain the patient's own biologic factors and support native tissue remodeling rather than scar formation. Fully resorbable within 3-4 months. Used by orthopedic surgeons for rotator cuff and other tendon-bone interface procedures.
• BioCharge Autobiologic Matrix Bioresorbable synthetic onlay scaffold for the bursal side of rotator cuff repairs with built-in delivery system and suture tunnel to reinforce the tendon-suture interface and deter suture cut-through. Resorbs in 4-6 months. Used by orthopedic surgeons for arthroscopic rotator cuff repair augmentation.
• Phoenix Wound Matrix 3D electrospun synthetic polymer matrix for reconstruction of non-healing wounds, supporting establishment of a native microbiome and promoting organized tissue granulation and remodeling. Resorbs in 10-14 days. Used by wound care specialists for full- to partial-thickness wounds, including those with exposed bone and tendon.
• ROTIUM LoPro Bioresorbable wick scaffold variant designed for tendon wrapping, onlay, and capsular closure applications. Resorbs in approximately 3 months. Used by orthopedic surgeons for tendon repair procedures beyond rotator cuff.
• BioStack Kit Dual-sided biologic strategy combining ROTIUM and BioCharge to address both the tendon-to-bone interface and the tendon-suture interface in rotator cuff repair, offering comprehensive biologic augmentation without additional fixation or disposables. Used by orthopedic surgeons performing rotator cuff repairs.

Quantifiable outcome

• 7.1% failure rate with ROTIUM vs 50% without augmentation in rotator cuff repair study (17-month follow-up)
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core, flagship and minor.

• RenovoDermcoreStrategic or Co-development Partner · 20 May 2026Atreon Orthopedics merged with RenovoDerm, combining their synthetic biomaterials platforms for tissue repair. The merger aims to expand applications and clinical evidence, supporting scalable growth across multiple surgical specialties. This merger unifies two high-growth, market-disrupting companies in a shared mission to deliver expanded regenerative solutions.
• Nanofiber SolutionscoreStrategic or Co-development PartnerAtreon Orthopedics was created in partnership with Nanofiber Solutions, which serves as the company's development and manufacturing partner. Nanofiber Solutions provides electrospun scaffold technology expertise and manufacturing capabilities. Dr. Jed Johnson is Co-Founder and CTO of Nanofiber Solutions.
• Orthopedic Innovation Consortium (OIC)flagshipStrategic or Co-development PartnerAtreon Orthopedics is one of the original founding companies of the Orthopedic Innovation Consortium, a collaborative community of medical device entrepreneurs, startups, and healthcare professionals working to accelerate orthopedic innovation through shared insights and strategic partnerships.
• ABANZAminorGTM or Marketing PartnerCo-hosted Orthopedic Innovation Consortium networking mixer at AOSSM 2025 alongside Atreon and other orthopedic innovators.
• GeistlichminorGTM or Marketing PartnerCo-hosted Orthopedic Innovation Consortium networking mixer at AOSSM 2025 alongside Atreon and other orthopedic innovators.
• Lipogems InternationalminorGTM or Marketing PartnerCo-hosted Orthopedic Innovation Consortium networking mixer at AOSSM 2025 alongside Atreon and other orthopedic innovators.
• Marrow Access TechnologiesminorGTM or Marketing PartnerCo-hosted Orthopedic Innovation Consortium networking mixer at AOSSM 2025 alongside Atreon and other orthopedic innovators.
• Pristine SurgicalminorGTM or Marketing PartnerCo-hosted Orthopedic Innovation Consortium networking mixer at AOSSM 2025 alongside Atreon and other orthopedic innovators.
• ReparelminorGTM or Marketing PartnerCo-hosted Orthopedic Innovation Consortium networking mixer at AOSSM 2025 alongside Atreon and other orthopedic innovators.
• TetrousminorGTM or Marketing PartnerCo-hosted Orthopedic Innovation Consortium networking mixer at AOSSM 2025 alongside Atreon and other orthopedic innovators.
• TYBR HealthminorGTM or Marketing PartnerCo-hosted Orthopedic Innovation Consortium networking mixer at AOSSM 2025 alongside Atreon and other orthopedic innovators.
• Winter InnovationsminorGTM or Marketing PartnerCo-hosted Orthopedic Innovation Consortium networking mixer at AOSSM 2025 alongside Atreon and other orthopedic innovators.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Vericel: Vericel develops autologous cell therapies and bioimplants (MACI, NexoBrid) for cartilage repair and wound care — adjacent regenerative technology competing for the same sports medicine and complex wound care budgets as Atreon.
• Integra LifeSciences: Integra LifeSciences markets regenerative tissue technologies including dermal matrices and dura substitutes, and through its orthopedic channel competes with both Atreon's tendon scaffolds and the Phoenix Wound Matrix.
• CONMED: CONMED's Sports Medicine business sells rotator cuff repair anchors and biologic patches (including allograft options) for soft tissue healing — a direct competitor to ROTIUM and BioCharge in the same shoulder and tendon repair procedure mix.
• MiMedx: MiMedx markets dehydrated amniotic membrane and placental tissue allografts for wound healing and soft tissue repair, addressing the same biologic augmentation and wound reconstruction indications as Atreon's products.
• Organogenesis: Organogenesis sells advanced wound care biologics (Apligraf, Dermagraft, NuShield) that overlap with Atreon's Phoenix Wound Matrix in the wound reconstruction and limb salvage segments.

Broad incumbents

• Smith+Nephew: Smith+Nephew's Sports Medicine & ENT business sells rotator cuff repair kits, healing augmentation scaffolds (REGENETEN, a bioinductive implant), and orthobiologics — directly overlapping with Atreon's ROTIUM and BioCharge in shoulder and tendon repair.
• Stryker: Stryker's Sports Medicine division (formerly Wright Medical) sells suture anchors and tendon repair devices, while its orthobiologics portfolio addresses soft tissue healing — competing with Atreon's synthetic electrospun scaffolds for share of the same surgical procedure.
• Arthrex: Arthrex is the dominant global sports medicine and soft tissue repair company, offering suture anchors, grafts, and biologics for rotator cuff and tendon procedures — the same surgeon call point Atreon targets, though Arthrex's portfolio spans thousands of SKUs across all of orthopedics.
• Zimmer Biomet: Zimmer Biomet's Sports Medicine, Surgical, and Foot & Ankle businesses market biologics, grafts, and augmentation products for rotator cuff and tendon repairs, competing with Atreon's portfolio across multiple of the same surgical indications.

Emerging players

• Tetrous: Tetrous is an early-stage orthopedic startup developing bone-tendon-bone regeneration products; it co-founded the Orthopedic Innovation Consortium with Atreon and competes in the same tendon and enthesis healing category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@atreonorthopedics
• LinkedInlinkedin.com/company/atreonorthopedics
• Xx.com/AtreonOrtho

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atreon Orthopedics